An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer (CheckMate 274)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02632409|
Recruitment Status : Recruiting
First Posted : December 16, 2015
Last Update Posted : February 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Various Advanced Cancer||Biological: Nivolumab Other: Placebo||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||640 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)|
|Actual Study Start Date :||February 11, 2016|
|Estimated Primary Completion Date :||April 30, 2020|
|Estimated Study Completion Date :||May 1, 2020|
Nivolumab dose as specified
Placebo Comparator: Placebo
Placebo dose as specified
- Disease free survival (DFS) [ Time Frame: Approximately 5 years after the first subject is randomized ]DFS defined as the time between the date of randomization and the date of first recurrence or death (of any cause) whichever occurs first.
- Non-Urothelial track recurrence free survival (NUTRFS) [ Time Frame: Approximately 5 years after the first subject is randomized ]NUTRFS is defined as the time between the date of randomization and the date of first local non urothelial tract or distant recurrence or death (of any cause), whichever occurs first.
- Disease specific survival (DSS) [ Time Frame: Approximately 5 years after the first subject is randomized ]DSS is defined the time between the date of randomization and the date of death due to disease (urothelial cancer).
- Overall survival (OS) [ Time Frame: Approximately 5 years after the first subject is randomized ]OS is defined as the time between the date of randomization and the date of death (of any cause).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02632409
|Contact: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:||Clinical.Trials@bms.com|
|Contact: First line of the email MUST contain NCT# and Site #.|
Show 187 Study Locations
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|